Advanced refractory solid tumors
Conditions
Interventions
Experience group :Immunotherapy
Sponsors
The Affiliated Hospital of Southwest Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) aged 18-75 years for cancer patients, regardless of gender; 2) patients diagnosed with cancer, sarcoma, lymphoma and other malignant tumors by histological biopsy; 3) patients undergoing first - and second-line (at least 2 schemes and above) treatment and efficacy evaluation; 4) patients who are unable to tolerate or unwilling to receive first - and second-line chemotherapy; 5) patients with expected survival of more than 2 months; 6) no other immunotherapy drugs were used within 4 weeks before participating in this study; 7) the patient agrees to participate in the test and has signed the informed consent.
Exclusion criteria
Exclusion criteria: 1) participated in other clinical trials within 4 weeks before the start of this study; 2) patients who are taking chemotherapy or taking immunosuppressive agents within 2 weeks before the start of this study; 3) there were uncontrollable severe cardiac toxicity, allergic and other side effects during anti-tumor therapy; 4) there is no clinical evidence to suggest that patients with severe or uncontrolled systemic disease, such as disease, researchers believe that patients are not suitable for to participate in the test including severe high blood pressure, heart disease, such as: heart disease (namely II and II above cardiac function); 5) there are active infections, such as hepatitis b, hepatitis c, tuberculosis, AIDS, etc., which are considered inappropriate for the researchers to participate in the clinical trial; 6) the ecg results indicated obvious abnormalities, which was deemed inappropriate for the researchers to participate in the clinical experiment;Brain disease, abnormal judgment; 7) pregnant or lactating women; 8) it was determined by the researchers that the patients who were not suitable for this study were not suitable. If any of the above answers is "yes", this subject cannot participate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| efficient;Survival rate;Adverse reaction; | — |
Countries
China
Contacts
Public ContactWen Qinglian
Department of Oncology, Affiliated Hospital of Southwest Medical University
Outcome results
None listed